Abstract:Preclinical and clinical data show a close relationship between high infiltration of tumor-associated macrophages (TAMs) and a poor prognosis in most types of tumors, thus targeting TAMs stands out as promising anticancer immunotherapies. Recent studies have demonstrated the anti-tumor effects of artemisinin via enhancing anti-tumor immunity within tumor microenvironment, but the underlying mechanism is still not clear. In the present study we uncovered an important role of dihydroartemisinin (DHA) in regulating intratumoral TAM polarization and anti-tumor immune responses in mouse Lewis Lung carcinoma model. We found that DHA inhibited Lewis Lung carcinoma progress, moderately decreased the frequencies of TAMs within tumor stroma, and significantly increased CD86 expression while decreased CD206 expression on TAMs which indicates the role of DHA in polarizing TAMs into a M1-like phenotype. Then, our in vitro data confirmed that DHA dose-dependently promoted macrophage M1 phenotype transition by increasing M1 phenotype-related molecules, meanwhile decreasing the expression of M2 phenotype-related molecules. In addition, DHA increased proinflammatory cytokine production, enhanced the phagocytic capacity while decreased anti-inflammatory cytokine production. Finally, in order to prove that AKT/mTOR signaling potentially mediated DHA-induced macrophage differentiation, we used rapamycin to specifically block the activity of mTOR and stimulated macrophages under M1 stimuli. Our data clearly showed that rapamycin significantly decreased DHA-induced M1-related phenotypes and proinflammatory cytokine expression. In summary, our study highlighted DHA as one of future potential therapeutic options for the development of novel anticancer immunotherapies in lung cancer.

Dihydroartemisinin Inhibits the Mammalian Target of Rapamycin-Mediated Signaling Pathways in Tumor Cells.

Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells

Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling.

Dihydroartemisinin: A Potential Natural Anticancer Drug

Dihydroartemisinin Exhibits Antitumor Activity Toward Hepatocellular Carcinoma in Vitro and in Vivo.

Dihydroartemisinin Inhibits Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Dihydroartemisinin Suppresses Pancreatic Cancer Cells Via a Microrna-Mrna Regulatory Network

Dihydroartemisinin Inhibits the Raf/ERK/MEK and PI3K/AKT Pathways in Glioma Cells.

Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9

Dihydroartemisinin Inhibits Melanoma by Regulating CTL/Treg Anti-Tumor Immunity and STAT3-mediated Apoptosis Via IL-10 Dependent Manner

Progress on the Study of Anti-tumor Mechanisms of Dihydroartemisinin

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma Through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Dihydroartemisinin Inhibits Epithelial-Mesenchymal Transition Progression in Medullary Thyroid Carcinoma Through the Hippo Signaling Pathway Regulated by Interleukin-6

Dihydroartemisinin Suppresses Growth of Squamous Cell Carcinoma A431 Cells by Targeting the Wnt/β-catenin Pathway

Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts

Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling

Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway

Dihydroartemisinin Inhibits Angiogenesis In Pancreatic Cancer By Targeting The Nf-Kappa B Pathway